ALPS Advisors’s AgomAb Therapeutics NV AGMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$719K Buy
64,778
+14,794
+30% +$191K ﹤0.01% 779
2026
Q2
$649K Buy
+49,984
New +$563K ﹤0.01% 837

Other funds holding AGMB

ALPS Advisors's AGMB Position: Q3 2026 in Review

ALPS Advisors increased its AgomAb Therapeutics NV (AGMB) stake by 30% in Q3 2026, buying an estimated $191K and bringing the position to 64,778 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #779.

ALPS Advisors first reported a position in AGMB in Q2 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.

  • ALPS Advisors held 64,778 shares of AgomAb Therapeutics NV worth $719K as of Q3 2026.
  • ALPS Advisors bought 14,794 AgomAb Therapeutics NV shares in Q3 2026, an estimated $191K.
  • AgomAb Therapeutics NV made up ﹤0.01% of ALPS Advisors's portfolio in Q3 2026, its #779 holding.
  • ALPS Advisors first reported a position in AgomAb Therapeutics NV in Q2 2026 and has held it in 2 quarters since.
  • 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.